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Pemphigoid diseases comprise a heterogeneous group of subepidermal autoimmune bullous 
diseases of the skin and mucosa. These autoimmune bullous diseases are characterized by au-
toantibodies that target distinct structural proteins of the basement membrane zone (BMZ), 
which are important for the integrity of the epidermis and dermis. Various subtypes of pem-
phigoid diseases can be differentiated, including bullous pemphigoid (BP), nonbullous pem-
phigoid, pemphigoid gestationis, anti-p200 pemphigoid, lichen planus pemphigoides, epider-
molysis bullosa acquisita (EBA), linear IgA disease (LAD), mucous membrane pemphigoid 
(MMP), and anti-laminin-332 MMP (anti-LN-332 MMP). Although the clinical presentations 
of pemphigoid diseases are heterogeneous, the subtypes differ in clinical symptoms, target anti-
gens, and the treatment and prognosis. This thesis is focused on the diagnosis and clinical pre-
sentations of various subtypes of pemphigoid diseases, encompassing laboratory, translational 
and clinical studies. 
In chapter 2 we give an introduction in the history of the disease, with insights from the first 
theses about bullous diseases from The Netherlands. Initially, the term pemphigus was used 
to describe a blister, without knowledge of the origin. Since 1953, the disease entity of bullous 
pemphigoid has been recognized based on histopathology. In the following years, the introduc-
tion of the diagnostic technique immunofluorescence microscopy was a breakthrough in diag-
nostic classification and further subtyping of pemphigoid diseases. Several decades ago, the 
clinical observations were already made that patients with bullous pemphigoid often had a pru-
ritic prodromal phase before skin blistering occurred. More recent insights show a subgroup 
of patients does not fulfill the typical clinical picture, but have atypical nonbullous clinical 
features that may persist without the development of skin blistering. These atypical nonbullous 
variants are not a rarity, but reported to comprise 20 to 40% of patients. We analyzed the clin-
ical and immunopathological features of the nonbullous variant of pemphigoid by systematic 
review in chapter 3. Besides pruritus, the most common skin lesions in nonbullous pemphigoid 
were erythematous and urticarial plaques, papules and nodules, or eczematous lesions. These 
skin lesions are frequently present in patients with other pruritic inflammatory skin diseases, 
and therefore clinicians may only be ascertained of misdiagnosis retrospectively when skin 
blisters appeared. Diagnosis of nonbullous pemphigoid in particular can be challenging; the 
mean diagnostic delay of reported cases was 22.6 months. It is not known yet why these pa-
tients do not develop skin blisters. 
Several studies reported detection of circulating autoantibodies against the BP target antigens 
BP180 or BP230 by immunoblot, ELISA or indirect immunofluorescence in subjects who do 
not fulfill the available criteria of bullous pemphigoid, such as elderly people, elderly peo-
ple with pruritus, and also healthy blood donors. In chapter 4 we evaluated the detection of 
BP-specific autoantibodies in serum of 374 subjects with nonbullous skin disorders who visited 
our outpatient dermatology clinic, in whom autoimmune bullous diseases were excluded based 
on negative direct immunofluorescence (DIF). In 13.6% of subjects at least one positive immu-
noserological test was found, mainly the BP180 NC16A and BP230 ELISAs and immunoblot 
with autoantibodies against BP230. No association was seen with pruritus, present in most 
patients due to various skin diseases. These findings address the questions whether these pem-
phigoid specific autoantibodies are associated with a pre-clinical stage of bullous pemphigoid 
or could be a risk factor for development of the disease, or represent false-positive results. A 
minor subgroup of 3.5% of patients showed multiple reactivity in tests of different methodolo-
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gy; by both indirect immunofluorescence on salt-split skin (IIF SSS), and ELISA and/or im-
munoblot. These patients showed clinical characteristics of nonbullous pemphigoid, but did not 
fulfill the available combined criteria for diagnosis of bullous pemphigoid, lacking positivity by 
DIF on a skin biopsy. However, no evidence based diagnostic criteria have been established 
yet. 
In chapter 5, we evaluated the optimal diagnostic strategy for bullous and nonbullous pem-
phigoid and aimed to develop much-needed minimal diagnostic criteria. We compared several 
pairwise performed diagnostic tests in a large cohort of 1125 subjects with suspected pemphi-
goid. To reflect the diagnostic process in daily practice and opposed to single test comparison, 
we used multivariable logistic regression analysis to assess the additional diagnostic value of 
various tests. One in four patients initially presented as having nonbullous pemphigoid. DIF 
was confirmed to be the most robust diagnostic test and was positive in 88% of patients, al-
though it was less sensitive in the subgroup of nonbullous pemphigoid (81%). The remaining 
approximately 11% of patients with negative DIF could mostly be identified by positivity in 
IIF SSS and confirmed with positivity in other immunoserological tests. The combined perfor-
mance of DIF and IIF identified 98.8% of patients; therefore these combined tests should be 
considered the minimal required laboratory tests for diagnosis to identify the vast majority of 
patients. The BP180 NC16A ELISA did not have added diagnostic value in addition to DIF 
and IIF SSS, with a considerable false-positivity rate. The subjects with nonbullous pemphi-
goid had significantly more often solely autoantibodies against BP230 and lower serum titers 
or absence of autoantibodies against BP180. The BP230 autoantibodies contributed mainly to 
positivity by IIF SSS in serum. The latter has been reported previously in literature and could 
be an explanation why false-negative DIF biopsies may occur, by missing the intracellular 
target of the BP230 protein. Based on our findings, the proposed minimal diagnostic criteria of 
pemphigoid consist of at least two positive out of three criteria: 1) pruritus and/or predominant 
cutaneous blisters, 2) positive linear IgG and/or Complement C3 depositions (in n-serrated 
pattern) along the BMZ by DIF on a skin biopsy, 3) positive epidermal side staining of IgG 
by IIF SSS on serum.
With ageing also comes itch. We hypothesized nonbullous pemphigoid might be an unrecog-
nized cause of pruritus, and that nursing home residents are a very high-risk population for 
pemphigoid with a high age on average and presence of associated neurodegenerative disease 
and polypharmacy. In chapter 6 we evaluated the prevalence of pruritus and pemphigoid in 
nursing home residents in the prospective SSENIOR study. The prevalence of 47% of pruritus 
confirmed the common presence of the burdensome complaint, often of chronic duration. Our 
findings showed a high prevalence of pemphigoid of 6%, a two-hundredfold higher prevalence 
compared to the general population (0.026%). Remarkably, more often patients with unrecog-
nized nonbullous pemphigoid were diagnosed than with bullous pemphigoid. This raises the 
question whether the typical clinical features of bullous pemphigoid indeed are typical, or pos-
sibly the atypical nonbullous clinical features are more frequent, but unrecognized within the 
spectrum of pemphigoid. These findings implicate serological screening for pemphigoid using 
IIF SSS is recommended in the diagnostic work-up of elderly people with moderate to severe 
pruritus, with or without skin blistering. It is hypothesized the strong association with neuro-
degenerative diseases could be explained a process of neurodegeneration or neuroinflammation 
and with a subsequent cross-reactive immune response between neuronal and cutaneous auto-
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antigens, driven by an age related loss of immunotolerance. Overall, these insights suggest 
pemphigoid might be considered a cutaneous autoimmune disease of the elderly, that is more 
than skin deep.
In chapter 7 we described differentiation of subtypes of pemphigoid diseases based on serra-
tion pattern analysis by DIF on a skin biopsy. Subtyping in pemphigoid diseases is of impor-
tance because of differences in treatment, prognosis and complications of the disease, such as 
a scarring phenotype and recalcitrant disease course in EBA and associated malignancy in 
anti-laminin-332 MMP. DIF serration pattern analysis has been used for more than a decade 
in Groningen to differentiate EBA with a u-serrated pattern from other pemphigoid diseases 
with an n-serrated pattern. We analyzed various technical aspects for implementation of the 
technique in routine diagnostics, by comparing the procedures and performance in two lab-
oratories, in Groningen and Lübeck, Germany. Technical factors such as transport medium, 
thickness of cryosections, microtome blade or observer did not significantly affect the recogni-
tion of the serration patterns. The serration pattern can be well identified, shown by the high 
inter-rater conformity of 95.7% and the fact that no erroneous serration patterns were classi-
fied. DIF serration pattern analysis is the most informative and cost-effective diagnostic test 
for pemphigoid diseases. Recognizing the pathognomonic u-serrated pattern may increase the 
number of diagnosed cases of EBA substantially, especially in seronegative cases.  
We further evaluated the ability to learn recognition of serrated patterns by testing observ-
ers with levels of expertise in chapter 8. Practice makes perfect in case of serration pattern 
analysis. However, the use of the rather simple technique as routine diagnostic method is still 
limited, possibly by a lack of experience with the distinctive patterns. The image-based online 
n-versus-u test and instruction video was created to stimulate practicing serration pattern anal-
ysis, to test the recognition rate in various observers, and to spread the knowledge about the 
technique. Improvement in recognition rate was seen after a short instruction independent of 
the level of expertise of the participant, with a mean recognition rate of nearly 80%. The train-
ing images and instruction video remain available at www.nversusu.umcg.nl. The u-serrated 
pattern was better recognized than the n-serrated pattern.
In chapter 9 we explored a novel automated technique of computer aided serration pattern 
recognition based on the fingerprint of EBA, the u-serrated pattern. The spikes or ridge-end-
ings of the u-serrated patterns are distinctive recognizable features. We developed an auto-
matic technique that identifies the basement membrane zone and detect the distinct u-serrated 
pattern with trainable (COSFIRE) filters that are only selective for ridge-endings. Finally, a 
score and region of interest is provided that indicates the reliability of pattern recognition. We 
achieved an average recognition rate of 82.2% in 180 DIF images, which equals or exceeds the 
manual recognition rate. The technique of ridge-endings detector can be used for other appli-
cations, such as vessel-endings in retinal fundus images, and minutiae detection in fingerprints. 
In chapter 10 we used the combined diagnostic techniques of IIF knockout analysis and ser-
ration pattern analysis to identify 12 patients with the rare subtype of anti-p200 pemphigoid. 
The subtype is probably under-recognized and misdiagnosed, because sophisticated serological 
techniques are needed for definitive diagnosis. The clinical features were heterogeneous and 
the acral distribution of blisters might be a clue for diagnosis. In contrast to Japanese patients, 
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no association with psoriasis was found and the diseases severity was higher than previously re-
ported. The circulating autoantibodies of patients with anti-p200 pemphigoid show dermal side 
binding of IgG by IIF SSS and serves as a first step for identification of anti-p200 pemphigoid. 
While autoantibodies against laminin γ1 were found in two-thirds of patients with anti-p200 
pemphigoid, the significance of anti-laminin γ1 antibodies and molecular identity of the target 
antigen remain unclear.
Finally, in chapter 11 we evaluated the treatment approach for bullous pemphigoid among der-
matologists and residents in dermatology in The Netherlands (n=175), and made a comparison 
with the treatment approach of British dermatologists (n=375). Bullous and nonbullous pem-
phigoid have a high burden of disease due to the intense pruritus and/or blistering. Because of 
the potential chronic relapsing disease course, an effective treatment approach is needed. The 
dermatologists and residents in dermatology from The Netherlands showed a high adherence 
to the treatment recommendation in The Netherlands of transcutaneous systemic clobetasol 
therapy, used by more than half of the participants of the survey. Treatment was often contin-
ued after clinical remission to prevent relapses. In contrast, dermatologists from the United 
Kingdom preferred a different treatment strategy with lesional application of topical cortico-
steroids and discontinuation after remission. This difference can be explained by variation in 
national guidelines and health service models, with practical factors regarding topical therapy. 
Systemic anti-inflammatory antibiotics were commonly used in both The Netherlands (73%) 
and UK (79%) as alternative or adjunctive treatment, mainly doxycycline. Half of the partici-
pants considered oral corticosteroids as first-line treatment, the majority (58%) with adjuvant 
immunosuppressive therapy. The survey should be repeated in the upcoming five years to eval-
uate whether dermatologists follow recent guidelines and implicate new results of clinical trials 
for treatment of bullous pemphigoid. 

